As Advair Sales Fall, GSK’s Witty Reminds Investors Launches Need Time
This article was originally published in The Pink Sheet Daily
GlaxoSmithKline’s sales of Advair nose-dived 15% in the first quarter due to pricing pressure and loss of insurance coverage. New respiratory products like Breo Ellipta have yet to make a dent toward shoring up respiratory sales.
You may also be interested in...
FDA approved GSK’s Anoro Ellipta as the first LABA/LAMA combination product in the U.S. for the maintenance treatment of COPD Dec. 18, positioning GSK to launch a second respiratory product months after launching Breo Ellipta.
Investors are closely following a Phase III study testing Wainua in ATTR cardiomyopathy, which could read out early in 2025.
It’s early days in the launch of Zurzuvae for postpartum depression, but Sage highlighted encouraging prescription trends during the company’s fourth quarter sales and earnings call.